New Research Reveals HCPs and Parents Are Interpreting the Same Vaccine Guidance in Opposite Ways — As CDC Reclassification Puts Six Major Vaccines in a Gray Zone
BOSTON–(BUSINESS WIRE)–#COVID19–ZoomRx has released its latest report, “Impact of Shared Clinical Decision-Making on Pediatric Vaccine Workflows,” a dual-audience study of 50 U.S. pediatric HCPs and 50 caregivers conducted after the HHS January 5, 2026 update, which moved six vaccines (Influenza, Rotavirus, Hep A, Hep B, Meningococcal, and COVID-19) from routine recommendation to SCDM status. The central finding: the routine childhood vaccine visit may be vanishing.
Key Findings
- 70% of HCPs expect more time explaining disease severity for SCDM vaccines; 52% anticipate countering more social media misinformation.
- 48% of HCPs worry SCDM signals vaccination is optional — yet 68% of caregivers see it as a personalized recommendation.
- 82% of HCPs are familiar with the updated CDC schedule; only 38% of caregivers are.
Note: The above findings are based on a limited sample and are not predictive of future outcomes.
“It adds probably, on average, at least two or three minutes per visit for each child… the problem is I don’t have any more time — so it’s straining my time.”
— Pediatric HCP, Community Practice
A New Acceptance Hierarchy: Flu and COVID-19 Require the Most Intensive Conversations
Mandated vaccines (DTaP, Polio, MMR) remain routine, anchored by school requirements. Rotavirus and Meningococcal are accepted with targeted messaging. Influenza and COVID-19 sit at the bottom — requiring HCPs to dismantle refusal, not just hesitancy. As high-volume, annually recurring vaccines, this represents a fundamental restructuring of the demand environment.
The Perception Gap
The most commercially significant finding is a structural misalignment between what HCPs communicate and what caregivers hear. While 68% of caregivers view SCDM as personalized guidance, 48% of HCPs report it reads as “optional” to parents — and 36% say it reinforces existing safety concerns. Meanwhile, HCPs consistently underestimate caregivers’ appetite for personalized recommendations — the top driver of decision comfort.
An Imperative for Manufacturers
ZoomRx identifies three priority actions for manufacturers: simplify the science with visual aids, equip HCPs with conversation tools for efficient and personalized dialogue, and educate caregivers before the visit to close the information gap.
“The SCDM reclassification has shifted significant commercial risk to vaccine manufacturers — and our data shows HCPs are feeling the strain while caregivers arrive with an information gap manufacturers can help close.”
— Varsha Sundaram, Product Lead at ZoomRx
Study Methodology
ZoomRx surveyed 50 pediatric HCPs and 50 caregivers (Jan 28–Feb 2, 2026) via quantitative surveys and qualitative interviews, with strict screening for pediatric expertise and active vaccination involvement. Full report at zoomrx.com.
About ZoomRx
ZoomRx is a global life sciences consultancy serving 19 of the top 20 global biopharmaceutical companies. Learn more.
Contacts
Media Inquiries
David Tran, Head of Growth Marketing
245 Main St., Floor 2
Cambridge, MA 02142
+1 (714) 875-8678
[email protected]
